AU2018236290B2 - MK2 inhibitors, synthesis thereof, and intermediates thereto - Google Patents

MK2 inhibitors, synthesis thereof, and intermediates thereto Download PDF

Info

Publication number
AU2018236290B2
AU2018236290B2 AU2018236290A AU2018236290A AU2018236290B2 AU 2018236290 B2 AU2018236290 B2 AU 2018236290B2 AU 2018236290 A AU2018236290 A AU 2018236290A AU 2018236290 A AU2018236290 A AU 2018236290A AU 2018236290 B2 AU2018236290 B2 AU 2018236290B2
Authority
AU
Australia
Prior art keywords
compound
formula
salt
base
scheme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018236290A
Other languages
English (en)
Other versions
AU2018236290A1 (en
Inventor
Gregg Brian Feigelson
Maryll E. Geherty
Richard Martin Heid Jr.
Mohit KOTHARE
Hon-Wah Man
Alexander L. Ruchelman
John F. Traverse
Kelvin Hin-Yeong Yong
Chengmin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2018236290A1 publication Critical patent/AU2018236290A1/en
Application granted granted Critical
Publication of AU2018236290B2 publication Critical patent/AU2018236290B2/en
Assigned to BRISTOL-MYERS SQUIBB COMPANY reassignment BRISTOL-MYERS SQUIBB COMPANY Request for Assignment Assignors: CELGENE CAR LLC
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
AU2018236290A 2017-03-16 2018-03-15 MK2 inhibitors, synthesis thereof, and intermediates thereto Ceased AU2018236290B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472024P 2017-03-16 2017-03-16
US62/472,024 2017-03-16
PCT/US2018/022547 WO2018170203A1 (en) 2017-03-16 2018-03-15 Mk2 inhibitors, synthesis thereof, and intermediates thereto

Publications (2)

Publication Number Publication Date
AU2018236290A1 AU2018236290A1 (en) 2019-09-19
AU2018236290B2 true AU2018236290B2 (en) 2022-06-02

Family

ID=63523971

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018236290A Ceased AU2018236290B2 (en) 2017-03-16 2018-03-15 MK2 inhibitors, synthesis thereof, and intermediates thereto

Country Status (8)

Country Link
US (2) US10894796B2 (cg-RX-API-DMAC7.html)
EP (1) EP3596086A4 (cg-RX-API-DMAC7.html)
JP (1) JP7282039B2 (cg-RX-API-DMAC7.html)
CN (1) CN110678471B (cg-RX-API-DMAC7.html)
AU (1) AU2018236290B2 (cg-RX-API-DMAC7.html)
CA (1) CA3054826A1 (cg-RX-API-DMAC7.html)
MX (1) MX387359B (cg-RX-API-DMAC7.html)
WO (1) WO2018170203A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
EP3596086A4 (en) 2017-03-16 2020-12-16 Celgene CAR LLC MK2 INHIBITORS, THEIR SYNTHESIS AND THEIR INTERMEDIARIES
JP2020511468A (ja) 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の重水素化アナログおよびその使用
EP3596084A4 (en) * 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4,5] THIÉNO [3,2-F] QUINOLIN-8-ONE COMPOUNDS AND THEIR USES
US11124525B2 (en) 2017-03-16 2021-09-21 Celgene Car Llc Heteroaryl compounds useful as MK2 inhibitors
AU2018236286B2 (en) 2017-03-16 2022-02-17 Bristol-Myers Squibb Company Forms and compositions of a MK2 inhibitor
WO2020236636A1 (en) * 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
EP4284805A1 (en) * 2021-02-01 2023-12-06 Celgene Corporation Mk2 inhibitors, the synthesis thereof, and intermediates thereto
WO2023025298A1 (zh) * 2021-08-27 2023-03-02 瑞石生物医药有限公司 喹啉并呋喃衍生物及其用途
EP4464694A4 (en) 2022-01-14 2026-04-01 Shanghai Hansoh Biomedical Co Ltd POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE
CN116643046B (zh) * 2023-05-30 2025-09-12 南昌市高新区人民医院(南昌大学第一附属医院高新医院) Mk2在癌症恶病质肌肉萎缩中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016044463A2 (en) * 2014-09-17 2016-03-24 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0317430A (pt) 2002-12-20 2005-10-25 Pharmacia Corp Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2010533674A (ja) 2007-07-16 2010-10-28 ノバルティス アーゲー Ｍｋ２阻害剤として有用なヘテロ環式化合物
JP5369173B2 (ja) 2008-04-22 2013-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キノリン若しくはイソキノリン置換ｐ２ｘ７アンタゴニスト
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2588455B1 (en) 2010-07-02 2018-04-04 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
CN103189377B (zh) * 2010-10-29 2015-02-25 辉瑞大药厂 N1/n2-内酰胺乙酰辅酶a羧化酶抑制剂
BR112013010564B1 (pt) * 2010-11-01 2021-09-21 Celgene Car Llc Compostos heterocíclicos e composições compreendendo os mesmos
DK2648516T3 (da) * 2010-12-06 2019-01-02 Aclaris Therapeutics Inc Substituerede pyridinon-pyridinylforbindelser
BR112015000399A2 (pt) 2012-07-10 2017-06-27 Ares Trading Sa derivados de pirazolil pirimidina
EP2872144A4 (en) * 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
US10138256B2 (en) 2013-03-15 2018-11-27 Celgene Car Llc MK2 inhibitors and uses thereof
CN104177340A (zh) * 2013-05-22 2014-12-03 中国中化股份有限公司 一种新型的喹唑啉（硫）酮类化合物及其用途
EP3110874B1 (en) 2014-02-27 2018-03-21 Council of Scientific and Industrial Research Poly-benzimidazole with pyrene and anthracene flourophore
WO2016025561A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor
WO2017040449A1 (en) 2015-09-03 2017-03-09 Bristol-Myers Squibb Company Triazolopyridine inhibitors of myeloperoxidase
EP3596084A4 (en) 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4,5] THIÉNO [3,2-F] QUINOLIN-8-ONE COMPOUNDS AND THEIR USES
JP2020511468A (ja) 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の重水素化アナログおよびその使用
US11124525B2 (en) 2017-03-16 2021-09-21 Celgene Car Llc Heteroaryl compounds useful as MK2 inhibitors
EP3596086A4 (en) 2017-03-16 2020-12-16 Celgene CAR LLC MK2 INHIBITORS, THEIR SYNTHESIS AND THEIR INTERMEDIARIES
AU2018236286B2 (en) 2017-03-16 2022-02-17 Bristol-Myers Squibb Company Forms and compositions of a MK2 inhibitor
WO2020236636A1 (en) 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
WO2022020562A1 (en) 2020-07-24 2022-01-27 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders
EP4284805A1 (en) 2021-02-01 2023-12-06 Celgene Corporation Mk2 inhibitors, the synthesis thereof, and intermediates thereto

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016044463A2 (en) * 2014-09-17 2016-03-24 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lian, Y. et al.; Org. Lett., 18, 1362-1365 (2016). DOI: 10.1021/acs.orglett.6b00295. *

Also Published As

Publication number Publication date
US20210139501A1 (en) 2021-05-13
US20200102326A1 (en) 2020-04-02
US10894796B2 (en) 2021-01-19
AU2018236290A1 (en) 2019-09-19
US11655257B2 (en) 2023-05-23
WO2018170203A1 (en) 2018-09-20
JP2020510063A (ja) 2020-04-02
CN110678471A (zh) 2020-01-10
EP3596086A4 (en) 2020-12-16
MX2019010642A (es) 2019-10-17
CA3054826A1 (en) 2018-09-20
JP7282039B2 (ja) 2023-05-26
MX387359B (es) 2025-03-18
EP3596086A1 (en) 2020-01-22
CN110678471B (zh) 2022-09-13

Similar Documents

Publication Publication Date Title
US11655257B2 (en) MK2 inhibitors, synthesis thereof, and intermediates thereto
AU2019364336B2 (en) TYK2 inhibitors and uses thereof
CN113024544B (zh) 一种含氰基并杂环化合物及其用途
ES2977683T3 (es) Derivados de bencimidazolona y análogos de los mismos, como moduladores de IL-17
CA2992408A1 (en) Substituted aza compounds as irak-4 inhibitors
WO2004096806A1 (ja) 縮合イミダゾール誘導体
CA2607780A1 (en) Purine derivatives
US10882867B2 (en) Forms and compositions of a MK2 inhibitor
RS62254B1 (sr) Derivati pirimidina za tretman virusnih infekcija
JPH06287188A (ja) 新規複素環誘導体
AU2005326659A1 (en) Multicyclic bis-amide MMP inhibitors
WO2005080330A1 (ja) ヘテロアリールフェニルウレア誘導体
AU2023351608A1 (en) Fused ring compound and pharmaceutical containing same
AU2021304045B2 (en) Immunomodulator
CN115028648B (zh) 三并环化合物及其药物组合物和应用
EP3596083A1 (en) Heteroaryl compounds useful as mk2 inhibitors
CN117222628B (zh) 一种抑制细胞程序性死亡的化合物及其制备方法
WO2023020209A1 (zh) 含2-芳杂环取代的脲类化合物、其制备方法和用途
US10093679B2 (en) Amino sulfonyl-based compounds, the preparation method therefor and use thereof
ES2663498T3 (es) Tetrahidro-tetrazolo[1,5-a]pirazinas como inhibidores de ROR-gamma
AU2005272298A1 (en) Pyrazolo[1,5-a]pyrimidine derivative
JP2018501282A (ja) チアゾール誘導体の製造方法
CA2583150A1 (en) 1,2,4-triazolylaminoaryl (heteroaryl) sulfonamide derivatives
AU2019394593A1 (en) Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof
US20250002505A1 (en) Synthesis of macroyclic compounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: BRISTOL-MYERS SQUIBB COMPANY

Free format text: FORMER OWNER(S): CELGENE CAR LLC

MK14 Patent ceased section 143(a) (annual fees not paid) or expired